Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Public ClinicalTrials.gov record NCT05173987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).
Study identification
- NCT ID
- NCT05173987
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 280 participants
Conditions and interventions
Conditions
Interventions
- pembrolizumab Biological
- carboplatin Drug
- paclitaxel Drug
- docetaxel Drug
- cisplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 3, 2022 (Actual)
- Primary completion
- May 27, 2027 (Estimated)
- Completion
- May 27, 2027 (Estimated)
- Last update posted
- May 5, 2026
2022 – 2027
United States locations
- U.S. sites
- 35
- U.S. states
- 22
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth-USOR HonorHealth ( Site 8000) | Phoenix | Arizona | 85016 | — |
| Moores Cancer Center ( Site 0037) | La Jolla | California | 92093-0698 | — |
| Kaiser Permanente Riverside Medical Center ( Site 0045) | Riverside | California | 92505 | — |
| Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0013) | New Haven | Connecticut | 06511 | — |
| Mount Sinai Cancer Center ( Site 0018) | Miami Beach | Florida | 33140 | — |
| Sarasota Memorial Heath Care System ( Site 0005) | Sarasota | Florida | 34239 | — |
| Northside Hospital ( Site 0017) | Atlanta | Georgia | 30342 | — |
| Southeastern Regional Medical Center ( Site 0046) | Newnan | Georgia | 30265 | — |
| Midwestern Regional Medical Center,Inc. DBA CTCA, Chicago ( Site 0003) | Zion | Illinois | 60099 | — |
| St. Vincent Hospital and Health Care Center, Inc ( Site 0006) | Indianapolis | Indiana | 46260 | — |
| Baptist Health Lexington ( Site 0042) | Lexington | Kentucky | 40503 | — |
| Maryland Oncology Hematology, P.A.-USOR Maryland Oncology Hematology, P.A. ( Site 8002) | Rockville | Maryland | 20850 | — |
| University of Massachusetts Medical School-Division of Gynecologic Oncology ( Site 0008) | Worcester | Massachusetts | 01605 | — |
| Karmanos Cancer Institute ( Site 0029) | Detroit | Michigan | 48201 | — |
| St. Dominic's Hospital ( Site 0024) | Jackson | Mississippi | 39216 | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026) | Hackensack | New Jersey | 07601 | — |
| The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0023) | New York | New York | 10011 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0016) | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai ( Site 0052) | New York | New York | 10029 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0009) | New York | New York | 10065 | — |
| FirstHealth Clinical Trials ( Site 0050) | Pinehurst | North Carolina | 28374 | — |
| Sanford Medical Center ( Site 0054) | Bismarck | North Dakota | 58501 | — |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0055) | Fargo | North Dakota | 58102 | — |
| University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0039) | Cincinnati | Ohio | 45219 | — |
| The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0027) | Columbus | Ohio | 43210 | — |
| Providence Portland Medical Center ( Site 0031) | Portland | Oregon | 97213 | — |
| Sidney Kimmel Cancer Center - Jefferson Health ( Site 0053) | Philadelphia | Pennsylvania | 19107 | — |
| University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0034) | Pittsburgh | Pennsylvania | 15213 | — |
| AHN West Penn Hospital ( Site 0011) | Pittsburgh | Pennsylvania | 15224 | — |
| Asplundh Cancer Pavilion ( Site 0014) | Willow Grove | Pennsylvania | 19090 | — |
| Sanford Cancer Center-Gynecologic Oncology ( Site 0002) | Sioux Falls | South Dakota | 57104 | — |
| Texas Oncology - Austin-USOR Texas Oncology - Austin ( Site 8003) | Austin | Texas | 78731 | — |
| Texas Oncology - Dallas-USOR Texas Oncology - Dallas (Sammons) ( Site 8005) | Dallas | Texas | 75246 | — |
| Texas Oncology - Tyler-USOR Texas Oncology - Northeast Texas ( Site 8004) | Tyler | Texas | 75702 | — |
| VCU Health Adult Outpatient Pavillion ( Site 0022) | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 159 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05173987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05173987 live on ClinicalTrials.gov.